Spotlight on Icosapent ethyl for cardiovascular risk reduction: Evidence to date

Authors

Xiaoming Jia, Baylor College of Medicine, HUSA.
Stephanie Koh, Baylor College of Medicine, USA.
Mahmoud Al Rifai, Baylor College of Medicine, USA.
Roger S. Blumenthal, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, USA.
Salim S. Virani, Baylor College of Medicine, USA.Follow

Document Type

Review Article

Department

Cardiology; Office of the Provost

Abstract

Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.

Comments

Issue no. is not provided by the author/publisher. This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Vascular Health and Risk Management

DOI

10.2147/VHRM.S210149

Recommended Citation

Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., Virani, S. S. (2020). Spotlight on Icosapent ethyl for cardiovascular risk reduction: Evidence to date. Vascular Health and Risk Management, 16, 1-10.
Available at: https://ecommons.aku.edu/provost_office/614

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License